Zai Lab (ZLAB) Stock Price, News & Analysis

Company Overview

Zai Lab Ltd. (NASDAQ: ZLAB) is a biopharmaceutical company focused on discovering, developing and commercializing medicines for serious diseases with significant unmet medical needs. The company’s research and development activities span oncology, autoimmune and inflammatory disorders, infectious diseases, and neuroscience.

Founded in 2014 by Samantha Du, Zai Lab has built a portfolio through internal research as well as licensing and collaboration agreements with international pharmaceutical and biotechnology companies. Its products and partnered therapies have included treatments such as ZEJULA (niraparib) for certain ovarian cancers, QINLOCK (ripretinib) for gastrointestinal stromal tumors, and NUZYRA (omadacycline), an antibiotic used to treat certain bacterial infections.

Zai Lab has historically concentrated on developing and commercializing innovative therapies in China while expanding its research, development and commercial capabilities internationally. The company’s operations have included activities in China, the United States and other global markets, supported by partnerships intended to broaden access to its medicines. Zai Lab was founded and led by Samantha Du, a biotechnology executive with experience in drug development and company building.

Key Stats

• Today's Range: $22.78 to $24.29
• 50-Day Range: $18.37 to $27.00
• 52-Week Range: $15.96 to $30.18
• Volume: 778,448 shs
• Average Volume: 804,684 shs
• Market Capitalization: $2.63 billion
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: $37.25
• Consensus Rating: Moderate Buy

Zai Lab Stock Analysis - MarketRank™

Zai Lab scored higher than 56% of companies evaluated by MarketBeat, and ranked 437th out of 877 stocks in the healthcare sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 4.0 / 5
• Analyst Rating: Moderate Buy

Consensus Rating

Zai Lab has received a consensus rating of Moderate Buy. The company's average rating score is 2.71, and is based on 1 strong buy rating, 4 buy ratings, 1 hold rating, and 1 sell rating.

Upside Potential

Zai Lab has a consensus price target of $37.25, representing about 61.3% upside from its current price of $23.10.

Amount of Analyst Coverage

Zai Lab has only been the subject of 3 research reports in the past 90 days.

Earnings and Valuation

• Score: 0.6 / 5
• Proj. Earnings Growth: Growing

Earnings Growth

Earnings for Zai Lab are expected to grow in the coming year, from ($2.37) to ($2.36) per share.

Price to Book Value per Share Ratio

Zai Lab has a P/B Ratio of 3.62. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

Short Interest

• Score: 3.0 / 5
• Short Interest Level: Healthy

Percentage of Shares Shorted

6.61% of the float of Zai Lab has been sold short.

Short Interest Ratio / Days to Cover

Zai Lab has a short interest ratio ("days to cover") of 9.04.

Change versus previous month

Short interest in Zai Lab has recently decreased by 12.35%, indicating that investor sentiment is improving significantly.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Zai Lab does not currently pay a dividend.

Dividend Growth

Zai Lab does not have a long track record of dividend growth.

News and Social Media

• Score: 1.6 / 5
• News Sentiment: 0.58

News Sentiment

Zai Lab has a news sentiment score of 0.58. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.70 average news sentiment score of Healthcare companies.

News Coverage This Week

MarketBeat has tracked 3 news articles for Zai Lab this week, compared to 3 articles on an average week.

Company Ownership

• Score: 1.4 / 5
• Insider Trading: Selling Shares

Insider Buying vs. Insider Selling

In the past three months, Zai Lab insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $235,145.00 in company stock.

Percentage Held by Insiders

4.88% of the stock of Zai Lab is held by insiders.

Percentage Held by Institutions

41.65% of the stock of Zai Lab is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

Company Calendar

• Last Earnings: 6/30/2026
• Today: 10/13/2026
• Investor update: 10/23/2026
• Next Earnings (Estimated): 11/05/2026
• Fiscal Year End: 12/31/2026

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Healthcare
• Industry: Biotechnology
• Sub-Industry: Biotechnology
• Current Symbol: NASDAQ:ZLAB
• CIK: 1704292
• Web: www.zailaboratory.com
• Phone: 862161632588
• Fax: 86-21-6163-2570
• Employees: 1,784
• Year Founded: 2014

Price Target and Rating

• Average Price Target for Zai Lab: $37.25
• High Price Target: $45.00
• Low Price Target: $32.00
• Potential Upside/Downside: +61.3%
• Consensus Rating: Moderate Buy
• Rating Score (0-4): 2.71
• Research Coverage: 7 Analysts

Profitability

• EPS (Trailing Twelve Months): ($1.71)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: -$175.54 million
• Net Margins: -41.86%
• Pretax Margin: -42.42%
• Return on Equity: -27.43%
• Return on Assets: -16.72%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 2.13
• Quick Ratio: 1.92

Sales & Book Value

• Annual Sales: $460.16 million
• Price / Sales: 5.71
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $6.39 per share
• Price / Book: 3.62

Miscellaneous

• Outstanding Shares: 113,780,000
• Free Float: 108,230,000
• Market Cap: $2.63 billion
• Optionable: Optionable
• Beta: 0.73